NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Forecast & News

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) issued its quarterly earnings results on Monday, November, 11th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.18. The biotechnology company had revenue of $15.13 million for the quarter, compared to analysts' expectations of $6.28 million. Pieris Pharmaceuticals had a negative return on equity of 132.02% and a negative net margin of 107.24%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Pieris Pharmaceuticals.

4 Wall Street analysts have issued 12-month target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Pieris Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 84.7% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

Media coverage about PIRS stock has been trending very negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a news sentiment score of -3.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Pieris Pharmaceuticals.

Pieris Pharmaceuticals saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,180,000 shares, a decrease of 32.6% from the January 15th total of 1,750,000 shares. Based on an average daily volume of 564,500 shares, the short-interest ratio is presently 2.1 days. Currently, 2.4% of the shares of the stock are sold short. View Pieris Pharmaceuticals' Current Options Chain.

Some companies that are related to Pieris Pharmaceuticals include Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Geovax Labs (GOVX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), US Stem Cell (USRM) and Vitality Biopharma (VBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Agile Therapeutics (AGRX), Omeros (OMER), Anavex Life Sciences (AVXL), Exelixis (EXEL), Marinus Pharmaceuticals (MRNS) and Nabriva Therapeutics (NBRV).

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (4.61%), Renaissance Technologies LLC (3.61%), Candriam Luxembourg S.C.A. (2.71%), State Street Corp (1.79%), Samsara BioCapital LLC (1.28%) and Parkman Healthcare Partners LLC (1.13%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Spark Investment Management LLC, Alpine Global Management LLC, Meeder Asset Management Inc. and Algert Global LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Candriam Luxembourg S.C.A., Samsara BioCapital LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Voss Capital LLC, Jacobs Levy Equity Management Inc. and Panagora Asset Management Inc.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $3.79.

Pieris Pharmaceuticals has a market capitalization of $208.37 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.

The official website for Pieris Pharmaceuticals is http://www.pieris.com/.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]